IOncology

At ASCO GI 2025, Anna Dorothea Wagner and colleagues presented the EORTC-1203 "INNOVATION" trial, investigating trastuzumab (T) ± pertuzumab (P) with perioperative chemotherapy (CT) in HER2+ gastric and esophagogastric junction…

At ASCO GI 2025, Thierry André and colleagues presented CheckMate 8HW results, showing nivolumab (NIVO) + ipilimumab (IPI) outperforms NIVO alone in MSI-H/dMMR metastatic colorectal cancer (mCRC).Key findings:✅ PFS significantly…

A new phase 3 study, led by Scott Kopetz and an international team, provides strong evidence supporting encorafenib + cetuximab (EC) with mFOLFOX6 as a first-line treatment for BRAF V600E-mutant…

A recent study led by Anna Martling, the ALASCCA trial, provides new evidence that low-dose aspirin (160 mg daily) can reduce recurrence risk in colorectal cancer (CRC) patients with PI3K…

Prostate cancer is one of the most common malignancies affecting the male genitourinary system, and in China, a significant proportion of newly diagnosed patients present with advanced disease. Since late-stage prostate cancer is symptomatic and not curable, alleviating symptoms, delaying disease progression, and improving quality of life have always been priorities for both patients and physicians in China. In 2024, several groundbreaking studies on advanced prostate cancer, including metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC), were published in leading medical journals and presented at international conferences, reshaping treatment paradigms. With a retrospective look at the past year, Oncology Frontier invited Dr. Dingwei Ye from Fudan University Shanghai Cancer Center to share insights on these advancements.

Introduction: Gastrointestinal (GI) cancers remain a significant challenge in oncology, with conventional therapies often yielding limited success in advanced cases. Recent advances in cellular therapies, particularly chimeric antigen receptor T-cell…

Prostate cancer is one of the most common malignancies threatening men's health worldwide. With population aging and lifestyle changes, the incidence of prostate cancer in China has been steadily increasing in recent years. As an early-stage disease, localized prostate cancer generally has a favorable prognosis, with curative potential through comprehensive treatment primarily centered on local interventions such as surgery. Enhancing the diagnosis and treatment of localized prostate cancer is key to improving overall survival rates for prostate cancer patients. Looking back at 2024, what were the major research advances in this field? This review will summarize key developments in screening and diagnosis, neoadjuvant therapy, surgical treatment, and the management of biochemical recurrence after surgery.

Breast cancer has become one of the most common malignancies among women, with triple-negative breast cancer (TNBC) being considered the most aggressive subtype due to its historically poor prognosis. Looking back at 2024, significant research breakthroughs have emerged in both early-stage and advanced TNBC treatment, covering chemotherapy, targeted therapy, immunotherapy, and antibody-drug conjugates (ADCs). Many of these studies have been led by Chinese researchers, contributing to original findings in the field. In this annual review, Dr. Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University shares the key advancements in systemic therapy for TNBC, showcasing how precision medicine is gradually transforming TNBC treatment and offering patients a brighter future.